跳至主要内容
临床试验/NCT00757029
NCT00757029已完成4 期

Association Between Norepinephrine Transporter Polymorphism and Response of Methylphenidate

Hallym University Medical Center1 个研究点 分布在 1 个国家目标入组 150 人开始时间: 2005年10月1日最近更新:
适应症
干预措施

试验速览

阶段
4 期
状态
已完成
入组人数
150
试验地点
1
主要终点
Korean ADHD Rating scale-parent version (KARS)

研究概览

简要总结

The noradrenergic system plays a known role in attentional systems and suspected causal role in attention deficit/hyperactivity disorder(ADHD).Methylphenidate also has been suspected as a inhibitor of norepinephrine transporter(SLC6A2). The investigators hypothesis is that norepinephrine transporter polymorphism is associated with responses and adverse effects of OROS-methylphenidate in treatment of ADHD.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
6 Years 至 18 Years(Child, Adult)
性别
All
接受健康志愿者
否

入选标准

  • •Physically healthy

排除标准

  • •Neurological illness
  • •Concurrent additional psychiatric treatment
  • •Psychotic disorder
  • •Major mood disorder needed other psychiatric medication
  • •Significant suicidal ideation
  • •Pervasive developmental disorder

研究组 & 干预措施

open label

Other

干预措施: norepinephrine transporter polymorphism, (Genetic)

结局指标

主要结局

Korean ADHD Rating scale-parent version (KARS)

时间窗: baseline,1,2,4,8 weeks

次要结局

  • Barkely side effect rating scale(1,2,4,8weeks)

研究者

申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验